Biotech News
Related news
PepGen
Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...
Recent company news
PEPGPepGen2026-08-06 11:32 EST
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPGPepGen2026-08-06 11:30 EST
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPGPepGen2026-05-21 11:00 EST
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPGPepGen2026-05-12 20:05 EST
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
PEPGPepGen2026-03-30 20:05 EST
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
Stock data
- Close
- 3.14 USD
- Market cap
- 100.3M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States